Purple Biotech Reaches Recommended Phase 2 Dose for NT219
REHOVOT, Israel, Feb. 01, 2024 (GLOBE NEWSWIRE) — Purple Biotech Ltd. (“Purple Biotech” or “the Company”) (NASDAQ/TASE: PPBT), a clinical-stage company developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance, today announced it has determined 100mg/kg is the recommended Phase 2 dose (RP2D) for NT219 in combination with cetuximab in the treatment of head and neck cancer based on its Phase 1/2 dose escalation study (NCT04474470). NT219 is a first-in-class small molecule dual inhibitor of IRS1/2 and STAT3.
Related news for (PPBT)
- 24/7 Market News Snapshot 04 September, 2025 – Purple Biotech Ltd. American Depositary Shares (NASDAQ:PPBT)
- MoBot’s Stock Market Highlights – 09/04/25 08:00 AM
- MoBot alert highlights: NASDAQ: HWH, NASDAQ: BBLG, NASDAQ: PPBT, NASDAQ: ZNB, NASDAQ: NCI (09/04/25 07:00 AM)
- 24/7 Market News Snapshot 04 September, 2025 – Purple Biotech Ltd. American Depositary Shares (NASDAQ:PPBT)
- Today’s Top Performers: MoBot’s Market Review 07/24/25 07:00 AM